• Rhythm Biosciences executes a supply and distribution agreement with Digistain Limited for its geneType genetic test portfolio in Southeast Asia
• Initial launch market is the Philippines, with potential to expand to additional Southeast Asian markets
• Agreement provides Rhythm with a baseline commercial floor and revenue visibility during market establishment

Rhythm Biosciences Ltd (ASX: RHY), a transformative, predictive cancer diagnostics technology company, has executed a Supply Agreement with Digistain Limited, a UK-incorporated cancer diagnostics company with an active international distribution footprint including in South East Asia, for the supply of the Company's geneType genetic test portfolio. The Agreement grants Digistain the right to market and distribute the geneType tests, commencing in the Philippines as an initial launch market, with the potential to include additional Southeast Asian markets as agreed by the parties. The Agreement has a 12-month initial term commencing 3rd March 2026, with renewal provisions supporting scalable regional expansion. The Agreement includes a structured pricing framework providing Rhythm with clear revenue visibility, and includes minimum volume commitments to establish a baseline commercial floor during market establishment. This Agreement represents Rhythm's first contracted commercial entry into Southeast Asia and establishes an initial revenue-generating distribution channel for geneType in the region. The inclusion of minimum volume commitments and per-test pricing provides a baseline level of expected activity during the initial term, with potential upside as additional markets are activated through Digistain's distribution network.

The Agreement does not include upfront payments or capital commitments from either party. Revenue to Rhythm will be generated on a per-test basis as samples are processed and reported, invoiced monthly with 30-day payment terms. The Company is unable to provide specific revenue guidance at this time given the early-stage nature of the initial Territory launch and the inherent uncertainty in forecasting adoption rates in a new market.

This agreement represents a meaningful step in translating Rhythm's geneType platform into commercial test volumes. Southeast Asia is a region where the company sees genuine long-term opportunity for genetic risk testing, and partnering with an established international distributor such as Digistain gives Rhythm a structured and capital-efficient pathway into these markets.